| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:1288759 | IVR | 400 mg/kg/day | 400 mg/kg/day | Changes in morphology of cervix | Reproductive endocrine-mediated perturbations |
| IVR | 400 mg/kg/day | 400 mg/kg/day | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:14691014 | IVTH | 0.00001 M | 0.00001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:25324206 | IVTH | 0.00003 M | 0.00003 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00003 M | 0.00003 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000003 M | 0.000003 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Affects androgen signaling | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000003 M | - | No significant effects observed | - | |
| PMID:25543211 | IVTH | 0.000001 - 0.0001 M | 0.00002 - 0.00004 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| PMID:6636195 | IVR | 6.3 mg/L | 6.3 mg/L | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 6.3 mg/L | 6.3 mg/L | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 203 mg/L | 203 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 203 mg/L | 203 mg/L | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 203 mg/L | 203 mg/L | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/L | 1 mg/L | Affects fertility | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.